EP1976540A1 - Treatment substance containing magnesium salts for treatment of tumors or like and use of magnesium salts - Google Patents
Treatment substance containing magnesium salts for treatment of tumors or like and use of magnesium saltsInfo
- Publication number
- EP1976540A1 EP1976540A1 EP06820070A EP06820070A EP1976540A1 EP 1976540 A1 EP1976540 A1 EP 1976540A1 EP 06820070 A EP06820070 A EP 06820070A EP 06820070 A EP06820070 A EP 06820070A EP 1976540 A1 EP1976540 A1 EP 1976540A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- treatment substance
- magnesium sulfate
- warts
- magnesium salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates on the one hand to a treatment substance containing magnesium salts for the treatment of tumors or the like, the treatment substance, used particularly for removing warts internally, being based, as regards its active ingredient, essentially on magnesium sulfate, and on the other hand to a novel use of magnesium sulfate.
- Warts (Verruca vulgaris) are tumor-like changes in the skin and believed to be caused especially by Papilloma virus. Warts may appear in various parts of the body, but mostly in the hands and feet. School children are particularly susceptible to developing warts, becoming exposed in their gymnastic/exercise activities, swimming pools, shower facilities, etc.
- warts are most commonly attended locally, e.g. by means of salicylic-acid containing bandaids and solutions, deep freezing, laser, surgery or electric needle treatments .
- the foregoing type of therapies usually necessitate the individual treatment of each wart, as a result of which a plurality of treatments are occasionally necessary, depending on the type of therapy and the number of warts.
- the results involve practically always cosmetic flaws, necessitating a meticulous postoperative care to avoid infections and to achieve a full recovery of the skin following a wart removal .
- the current treatments of warts often involve not only cosmetic flaws but also outright pains. In the event that warts develop in abundance, the above type of treatments become impossible to conduct in a single session but, instead, the removal of warts must be sequenced over a longer period of time unless the warts disappear by themselves after starting the removal process.
- Magnesium-containing products have been used in various therapies, e.g. as antacids, laxative and purgative preparations, but also as anticonvulsants and sedatives .
- the publication DE 19541735 discloses a solution, which is intended for the use of hydrothermal composite preparations, containing not only magnesium but also numerous other ingredients, in the treatment of e.g. skin problems, warts, orange-peel skin, psoriasis, acne, etc., not only by subcutaneous application but also in the form of e.g. bath salts, soaps, lotions, massage oils, sun screens, etc., or else e.g. in the form of tablets or solutions for oral administration.
- Prior known are also a plurality of magnesium-sulfate containing compositions for internal dosage.
- Orally administered compositions for removing warts have been described e.g. in the International patent publication WO 99/38517.
- the objective in using a treatment substance of the invention, containing magnesium salts, and in using magnesium sulfate is to provide a decisive improvement regarding the above problems and to thereby raise substantially the existing state of the art.
- the features, principally characteristic of a treatment substance of the invention, containing magnesium salts, and of a novel use of magnesium sulfate are presented in the characterizing clauses of the independent claims directed to two alternative implementations of each of them.
- a treatment substance of the invention and a novel application of magnesium sulfate enable a rapid and safe therapy, particularly for the removal of warts by the activity of an internally administered, magnesium-sulfate based treatment substance without a risk of the treatment causing e.g. swallowing, gullet or gastric trouble for a person being attended.
- the therapy conducted with a treatment substance of the invention provides positive results with extremely slight or totally without side effects over a treatment period which in the best case scenario is less than a week, the treatment resulting in a simultaneous disappearance of warts from the patient's skin, even from various extremities.
- a trouble-free repetition of the therapy, conducted with a treatment substance of the invention is also possible in the event that warts reoccurring.
- a principal benefit offered by the invention lies in the fact that a treatment substance, which lends itself to easy and agreeable internal administration, enables a simultaneous treatment of warts present even in various parts of the body, the warts disappearing by themselves during the course of the treatment with no need for after-care and/or corrective measures of the skin that are usually required in local treatments.
- the invention relates first of all to a treatment substance containing magnesium salts for the treatment of tumors or the like, the treatment substance, used particularly for removing warts internally, being based, as regards its active ingredient, essentially on magnesium sulfate.
- the treatment substance is formulated for anal administration, such as in the form of a suppository or the like. This enables avoiding the problems caused by oral administration of the treatment substance.
- the single dose of magnesium sulfate delivered by the treatment substance is 715-1200, most preferably 950 g, administered three times a day for the period of at least a week.
- the treatment substance is formulated for a solution administered as a subcutaneous or submucuous injection.
- a solution administered as a subcutaneous or submucuous injection is formulated for a solution administered as a subcutaneous or submucuous injection.
- the invention relates also to the use of magnesium sulfate by anal administration, such as in the form of a suppository or the like, in the manufacture of a treatment substance used particularly for the removal of warts .
- the invention relates to the use of magnesium sulfate in the manufacture of a treatment substance, the single dose of magnesium sulfate delivered thereby being 715-1200, most preferably 950 g, administered three times a day for the period of at least a week.
- the invention enables the use of magnesium sulfate also in the manufacture of a solution for administration as a subcutaneous or submucuous injection, particularly for the removal of warts.
- the therapy enabled by the invention has been subjected to practical testing, specifically by using a treatment solution with 20 g of magnesium sulfate and 280 ml of purified water .
- the test group was divided in two, the first faction being treated with a magnesium-sulfate based treatment substance and the second faction with a placebo treatment.
- the therapy was conducted with identical single doses for each group in either one- or two-week long treatment periods, after which it was verifiable that the magnesium-sulfate based therapy provided invariably a good result as all warts in the attended patients disappeared.
- the therapy not a single cure of warts was found in the therapy given as a placebo treatment.
- the patients of this second group were thereafter subjected to a therapy based on magnesium sulfate, the healing result was again positive as the warts disappeared in the best case in one and a half weeks.
- the invention is not limited to the foregoing embodiments as it can be varied within the same basic concept, e.g. in such a way that the treatment substance includes suitable dyes, excipients and/or additives used as its per se inert ingredients.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20060065A FI119101B (fi) | 2006-01-24 | 2006-01-24 | Magnesiumsuoloja sisältävä hoitoaine kasvainten tai vastaavien hoitoon ja magnesiumsulfaatin käyttö |
PCT/FI2006/000394 WO2007085681A1 (en) | 2006-01-24 | 2006-11-29 | Treatment substance containing magnesium salts for treatment of tumors or like and use of magnesium salts |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1976540A1 true EP1976540A1 (en) | 2008-10-08 |
EP1976540A4 EP1976540A4 (en) | 2010-07-28 |
Family
ID=35883876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06820070A Withdrawn EP1976540A4 (en) | 2006-01-24 | 2006-11-29 | THERAPEUTIC SUBSTANCE CONTAINING MAGNESIUM SALTS FOR THE TREATMENT OF TUMORS OR SIMILAR, AND USE OF MAGNESIUM SALTS |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1976540A4 (zh) |
FI (1) | FI119101B (zh) |
WO (1) | WO2007085681A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1499984A (en) * | 1975-04-16 | 1978-02-01 | Unigate Foods Ltd | Dietary foods |
WO1995031991A2 (en) * | 1994-05-25 | 1995-11-30 | Giampiero Valletta | Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
AU5589594A (en) * | 1992-10-29 | 1994-05-24 | C-P Technology Limited Partnership | Mixtures or complexes containing calcium and sulfate |
FI980216A0 (fi) * | 1998-01-30 | 1998-01-30 | Bene Pharma Oy | Medicin foer behandling av vaorfor |
-
2006
- 2006-01-24 FI FI20060065A patent/FI119101B/fi not_active IP Right Cessation
- 2006-11-29 EP EP06820070A patent/EP1976540A4/en not_active Withdrawn
- 2006-11-29 WO PCT/FI2006/000394 patent/WO2007085681A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1499984A (en) * | 1975-04-16 | 1978-02-01 | Unigate Foods Ltd | Dietary foods |
WO1995031991A2 (en) * | 1994-05-25 | 1995-11-30 | Giampiero Valletta | Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases |
Non-Patent Citations (4)
Title |
---|
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1976, ZAROW: "Clinical Observations on the Treatment of Verruca Peruana with Magnesium Sulfate" XP002105003 retrieved from BIOSIS accession no. PREV197764045827 Database accession no. PREV197764045827 * |
DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1957, NAGNEEBEDA N I: "The treatment of far advanced malignant tumours with magnesium sulphate" XP002586659 Database accession no. EMB-0007482898 & VOPROSY ONKOLOGII 1957, vol. 3, no. 5, 1957, pages 562-567, ISSN: 0507-3758 * |
MILLS B J ET AL: "Inhibition of tumor growth by magnesium depletion of rats." THE JOURNAL OF NUTRITION APR 1984 LNKD- PUBMED:6716176, vol. 114, no. 4, April 1984 (1984-04), pages 739-745, XP002586660 ISSN: 0022-3166 * |
See also references of WO2007085681A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007085681A1 (en) | 2007-08-02 |
FI119101B (fi) | 2008-07-31 |
EP1976540A4 (en) | 2010-07-28 |
FI20060065A0 (fi) | 2006-01-24 |
FI20060065A (fi) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5589480A (en) | Topical application of opioid analgesic drugs such as morphine | |
EA032439B1 (ru) | Композиции и способы для лечения поверхностных ран | |
CN108853312A (zh) | 聚桂醇外用凝胶及其制备方法 | |
DK166479B (da) | Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning | |
RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
US5278172A (en) | Method and composition for treating tendon or joint inflammation using a vasodilator | |
CN102188572B (zh) | 一种治疗骨伤的中药 | |
CN103977194A (zh) | 能有效治疗创面感染的外用药在制备治疗糖尿病足药物中的应用 | |
US5576329A (en) | Method for treating tendon or joint inflammation with papaverine HCL | |
EP2322177B1 (en) | Use of a preparation based on nifedipine for treating vaginismus | |
JPH08500343A (ja) | セシウムイオンを用いた治療方法 | |
WO2007085681A1 (en) | Treatment substance containing magnesium salts for treatment of tumors or like and use of magnesium salts | |
CN1669562A (zh) | 筋骨康复膏及其制备方法 | |
CN103585257B (zh) | 一种治疗骨折的中药散剂 | |
CN102078516B (zh) | 一种治疗骨伤的中药 | |
CN102512650A (zh) | 一种治疗面神经麻痹的外用药物 | |
CN104056080A (zh) | 一种治疗脑血栓后遗症的中药组合物 | |
RU2357747C1 (ru) | Способ лечения больных псориатической болезнью | |
RU2181995C1 (ru) | Способ лечения миофасциального болевого синдрома | |
CN107569577A (zh) | 一种药物组合物在制备治疗三叉神经痛的药物中的应用 | |
RU2286791C1 (ru) | Способ лечения рубцов | |
CN103110748B (zh) | 一种治疗性病的复方中药组合物及其用途 | |
RU2200557C1 (ru) | Способ лечения гипертрофических и келоидных рубцов | |
RU2182006C2 (ru) | Способ лечения ревматоидного артрита | |
Efraimidis et al. | Efficacy of laser application for the rehabilitation of patients with Bell's palsy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080806 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HONKANEN, KARI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/02 20060101ALN20100615BHEP Ipc: A61K 9/00 20060101ALI20100615BHEP Ipc: A61P 35/00 20060101ALI20100615BHEP Ipc: A61P 17/12 20060101ALI20100615BHEP Ipc: A61K 33/06 20060101AFI20070906BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100628 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110126 |